Germany - Drugs
For more information and to make a bid you will need to go to the third party website.
Details
Provided by
- Opportunity closing date
- 11 November 2024
- Opportunity publication date
- 22 November 2021
- Category
- 33600000: Ph
- Value of contract
- £0-100k
- Your guide to exporting
Description
§ Section 130a (8) SGB V enables health insurance funds (KK) and pharmaceutical companies to conclude framework discount agreements on drugs to be dispensed at the expense of the statutory KK. GWQ acts as a company for efficiency and quality at KK according to § 130a Abs. 8 S. 5 SGBV for its shareholder and customer health insurances. With regard to the relevant legal regulations for the awarding of public contracts, a regular process of active ingredient-related, formal award procedures in accordance with the regulations of Part 4 of the GWB is carried out by GWQ ServicePlus AG. Until the entry into force of new drug rebate contracts, GWQ would like to conclude drug rebate contracts with all interested pharmaceutical companies within the framework of the open house procedure for glycopyrronium/indacaterol. The start of the contract is 01.01.2022.
GWQ ServicePlus AG intends to conclude non-exclusive rebate agreements in accordance with § 130a Para. 8 SGB V for the above-mentioned active ingredient with a contract start date of 01/01/2022. All interested companies can join this agreement at any time during the term of the agreement under the same conditions (approval model). GWQ assumes that this procedure does not fall within the scope of application of cartel procurement law due to the lack of a selection decision and thus the non-discriminatory access of all pharmaceutical companies. The contract documents, the participating health insurance companies and their sales as well as the dates for the notification of the contract can be viewed and downloaded on the contract award portal of GWQ ServicePlus AG under http://vergabeportal.gwq-serviceplus.de. Until the start of exclusive contracts, this transitional agreement is open to all market participants to join.Upon receipt of the signed contracts / declaration and evidence by 10.12.2021, an initial notification can be realized on 01.01.2022.The following documents are to be submitted:- signed contract in duplicate;- proof of drug regulatory approval by means of an extract from the public part of the AMIce database;- signed self-declaration (Annex 3).- list of PZNs subject to the contract (Annex 2).
- Opportunity closing date
- 11 November 2024
- Value of contract
- £0-100k
About the buyer
- Address
- GWQ ServicePlus AG GWQ ServicePlus AG, Tersteegenstraße 28, 40474 Düsseldorf, handelnd für die unter VI 2.) näher genannten Gesetzlichen Krankenkassen Düsseldorf 40474 Germany
- Contact
- bieteranfrage@gwq-serviceplus.de
Bid for tender
If your company meets the requirements of the tender, go to the website where the tender is hosted and submit your bid.
This website contains links to other websites that we do not control or maintain. We are not responsible for the content of these sites. We provide these links for your convenience only, and do not necessarily endorse their content.
Before entering into a contract you need to apply for any necessary export licences, which can include applications to trade in certain goods. You should also make your own enquiries and be satisfied by the accuracy of any information supplied to you.
This opportunity has been translated from its original language. You should check if you need to apply in the original language.